This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): FE999301, FE-999301, FE-301, FE301, sgp130Fc
Description: FE 999301 is a soluble gp130Fc (sgp130Fc) fusion protein that targets IL-6 (Interleukin-6). IL-6 is a pleiotropic cytokine, and its dysregulation is involved in many diseases including chronic inflammatory and autoimmune disorders. gp130Fc interacts with IL-6 and the IL-6 receptor as part of IL-6 signaling.
Ferring and Conaris
In December 2008, Ferring and Conaris completed an exclusive worldwide license agreement for the development of FE301, a new recombinant protein inhibitor of the IL-6 pathway for inflammatory conditions such as IBD and rheumatoid arthritis.
Additional information available to subscribers only: